A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors

The aim of the Phase Ia portion is to identify the maximum tolerated dose or maximum acceptable dose MTD/MAD of HS-10516. The phase Ib portion will evaluate the preliminary efficacy of HS-10516 in patients with VHL Syndrome Associated Tumors.

Trial Details

NCT ID

NCT06553339

Phase

PHASE1

Sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Kidney Cancer

Interventions

Oral HS-10516

Locations (sample)

Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

Male or female from 18 to 80 year-old
Patients with advanced clear cellrenal cell carcinoma or von Hippel-Lindau Syndrome associated tumors
Has an Eastern Cooperative Oncology Group performance status of 0-1
Has a life expectancy of ≥ 12 weeks

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →